Enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for metastatic urothelial cancer, data suggest.

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug ...

Study finds enfortumab vedotin + pembrolizumab significantly boosts survival in advanced urothelial carcinoma patients ...

Since September 2024, enfortumab vedotin in combination with pembrolizumab has also been approved for the first-line treatment of unresectable or metastatic urothelial carcinoma. The German ...

The combination of enfortumab vedotin and pembrolizumab has shown promising clinical outcomes. The approval of multiple novel drugs and combination therapies not only provides new opportunities for ...

Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301] Technology appraisal guidance Pembrolizumab with ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332] Technology appraisal ...